BIRC5 expression by race, age and clinical factors in breast cancer patients
Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent. We studied BIRC5 expression in association...
Saved in:
| Published in | Breast cancer research : BCR Vol. 26; no. 1; pp. 50 - 11 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
21.03.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent.
We studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer. For comparison, similar analyses were conducted in The Cancer Genome Atlas [TCGA N = 1094, Black (n = 183), younger (n = 295)]. BIRC5 was evaluated as a continuous and categorical variable (highest quartile vs. lower three quartiles).
Univariate, continuous BIRC5 expression was higher in breast tumors from Black women relative to non-Black women in both estrogen receptor (ER)-positive and ER-negative tumors and in analyses stratified by stage (i.e., within Stage I, Stage II, and Stage III/IV tumors). Within CBCS and TCGA, BIRC5-high was associated with young age (< 50 years) and Black race, as well as hormone receptor-negative tumors, non-Luminal A PAM50 subtypes, advanced stage, and larger tumors (> 2 cm). Relative to BIRC5-low, BIRC5-high tumors were associated with poor 5-year recurrence-free survival (RFS) among ER-positive tumors, both in unadjusted models [HR (95% CI): 2.7 (1.6, 4.6)] and after adjustment for age and stage [Adjusted HR (95% CI): 1.87 (1.07, 3.25)]. However, this relationship was not observed among ER-negative tumors [Crude HR (95% CI): 0.7 (0.39, 1.2); Adjusted HR (95% CI): 0.67 (0.37, 1.2)].
Black and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes. |
|---|---|
| AbstractList | Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent.
We studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer. For comparison, similar analyses were conducted in The Cancer Genome Atlas [TCGA N = 1094, Black (n = 183), younger (n = 295)]. BIRC5 was evaluated as a continuous and categorical variable (highest quartile vs. lower three quartiles).
Univariate, continuous BIRC5 expression was higher in breast tumors from Black women relative to non-Black women in both estrogen receptor (ER)-positive and ER-negative tumors and in analyses stratified by stage (i.e., within Stage I, Stage II, and Stage III/IV tumors). Within CBCS and TCGA, BIRC5-high was associated with young age (< 50 years) and Black race, as well as hormone receptor-negative tumors, non-Luminal A PAM50 subtypes, advanced stage, and larger tumors (> 2 cm). Relative to BIRC5-low, BIRC5-high tumors were associated with poor 5-year recurrence-free survival (RFS) among ER-positive tumors, both in unadjusted models [HR (95% CI): 2.7 (1.6, 4.6)] and after adjustment for age and stage [Adjusted HR (95% CI): 1.87 (1.07, 3.25)]. However, this relationship was not observed among ER-negative tumors [Crude HR (95% CI): 0.7 (0.39, 1.2); Adjusted HR (95% CI): 0.67 (0.37, 1.2)].
Black and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes. Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent.PURPOSESurvivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent.We studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer. For comparison, similar analyses were conducted in The Cancer Genome Atlas [TCGA N = 1094, Black (n = 183), younger (n = 295)]. BIRC5 was evaluated as a continuous and categorical variable (highest quartile vs. lower three quartiles).EXPERIMENTAL DESIGNWe studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer. For comparison, similar analyses were conducted in The Cancer Genome Atlas [TCGA N = 1094, Black (n = 183), younger (n = 295)]. BIRC5 was evaluated as a continuous and categorical variable (highest quartile vs. lower three quartiles).Univariate, continuous BIRC5 expression was higher in breast tumors from Black women relative to non-Black women in both estrogen receptor (ER)-positive and ER-negative tumors and in analyses stratified by stage (i.e., within Stage I, Stage II, and Stage III/IV tumors). Within CBCS and TCGA, BIRC5-high was associated with young age (< 50 years) and Black race, as well as hormone receptor-negative tumors, non-Luminal A PAM50 subtypes, advanced stage, and larger tumors (> 2 cm). Relative to BIRC5-low, BIRC5-high tumors were associated with poor 5-year recurrence-free survival (RFS) among ER-positive tumors, both in unadjusted models [HR (95% CI): 2.7 (1.6, 4.6)] and after adjustment for age and stage [Adjusted HR (95% CI): 1.87 (1.07, 3.25)]. However, this relationship was not observed among ER-negative tumors [Crude HR (95% CI): 0.7 (0.39, 1.2); Adjusted HR (95% CI): 0.67 (0.37, 1.2)].RESULTSUnivariate, continuous BIRC5 expression was higher in breast tumors from Black women relative to non-Black women in both estrogen receptor (ER)-positive and ER-negative tumors and in analyses stratified by stage (i.e., within Stage I, Stage II, and Stage III/IV tumors). Within CBCS and TCGA, BIRC5-high was associated with young age (< 50 years) and Black race, as well as hormone receptor-negative tumors, non-Luminal A PAM50 subtypes, advanced stage, and larger tumors (> 2 cm). Relative to BIRC5-low, BIRC5-high tumors were associated with poor 5-year recurrence-free survival (RFS) among ER-positive tumors, both in unadjusted models [HR (95% CI): 2.7 (1.6, 4.6)] and after adjustment for age and stage [Adjusted HR (95% CI): 1.87 (1.07, 3.25)]. However, this relationship was not observed among ER-negative tumors [Crude HR (95% CI): 0.7 (0.39, 1.2); Adjusted HR (95% CI): 0.67 (0.37, 1.2)].Black and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes.CONCLUSIONBlack and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes. Abstract Purpose Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent. Experimental design We studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer. For comparison, similar analyses were conducted in The Cancer Genome Atlas [TCGA N = 1094, Black (n = 183), younger (n = 295)]. BIRC5 was evaluated as a continuous and categorical variable (highest quartile vs. lower three quartiles). Results Univariate, continuous BIRC5 expression was higher in breast tumors from Black women relative to non-Black women in both estrogen receptor (ER)-positive and ER-negative tumors and in analyses stratified by stage (i.e., within Stage I, Stage II, and Stage III/IV tumors). Within CBCS and TCGA, BIRC5-high was associated with young age (< 50 years) and Black race, as well as hormone receptor-negative tumors, non-Luminal A PAM50 subtypes, advanced stage, and larger tumors (> 2 cm). Relative to BIRC5-low, BIRC5-high tumors were associated with poor 5-year recurrence-free survival (RFS) among ER-positive tumors, both in unadjusted models [HR (95% CI): 2.7 (1.6, 4.6)] and after adjustment for age and stage [Adjusted HR (95% CI): 1.87 (1.07, 3.25)]. However, this relationship was not observed among ER-negative tumors [Crude HR (95% CI): 0.7 (0.39, 1.2); Adjusted HR (95% CI): 0.67 (0.37, 1.2)]. Conclusion Black and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes. Purpose Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent. Experimental design We studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer. For comparison, similar analyses were conducted in The Cancer Genome Atlas [TCGA N = 1094, Black (n = 183), younger (n = 295)]. BIRC5 was evaluated as a continuous and categorical variable (highest quartile vs. lower three quartiles). Results Univariate, continuous BIRC5 expression was higher in breast tumors from Black women relative to non-Black women in both estrogen receptor (ER)-positive and ER-negative tumors and in analyses stratified by stage (i.e., within Stage I, Stage II, and Stage III/IV tumors). Within CBCS and TCGA, BIRC5-high was associated with young age (< 50 years) and Black race, as well as hormone receptor-negative tumors, non-Luminal A PAM50 subtypes, advanced stage, and larger tumors (> 2 cm). Relative to BIRC5-low, BIRC5-high tumors were associated with poor 5-year recurrence-free survival (RFS) among ER-positive tumors, both in unadjusted models [HR (95% CI): 2.7 (1.6, 4.6)] and after adjustment for age and stage [Adjusted HR (95% CI): 1.87 (1.07, 3.25)]. However, this relationship was not observed among ER-negative tumors [Crude HR (95% CI): 0.7 (0.39, 1.2); Adjusted HR (95% CI): 0.67 (0.37, 1.2)]. Conclusion Black and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes. PurposeSurvivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent.Experimental designWe studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer. For comparison, similar analyses were conducted in The Cancer Genome Atlas [TCGA N = 1094, Black (n = 183), younger (n = 295)]. BIRC5 was evaluated as a continuous and categorical variable (highest quartile vs. lower three quartiles).ResultsUnivariate, continuous BIRC5 expression was higher in breast tumors from Black women relative to non-Black women in both estrogen receptor (ER)-positive and ER-negative tumors and in analyses stratified by stage (i.e., within Stage I, Stage II, and Stage III/IV tumors). Within CBCS and TCGA, BIRC5-high was associated with young age (< 50 years) and Black race, as well as hormone receptor-negative tumors, non-Luminal A PAM50 subtypes, advanced stage, and larger tumors (> 2 cm). Relative to BIRC5-low, BIRC5-high tumors were associated with poor 5-year recurrence-free survival (RFS) among ER-positive tumors, both in unadjusted models [HR (95% CI): 2.7 (1.6, 4.6)] and after adjustment for age and stage [Adjusted HR (95% CI): 1.87 (1.07, 3.25)]. However, this relationship was not observed among ER-negative tumors [Crude HR (95% CI): 0.7 (0.39, 1.2); Adjusted HR (95% CI): 0.67 (0.37, 1.2)].ConclusionBlack and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes. Abstract Purpose Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent. Experimental design We studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer. For comparison, similar analyses were conducted in The Cancer Genome Atlas [TCGA N = 1094, Black (n = 183), younger (n = 295)]. BIRC5 was evaluated as a continuous and categorical variable (highest quartile vs. lower three quartiles). Results Univariate, continuous BIRC5 expression was higher in breast tumors from Black women relative to non-Black women in both estrogen receptor (ER)-positive and ER-negative tumors and in analyses stratified by stage (i.e., within Stage I, Stage II, and Stage III/IV tumors). Within CBCS and TCGA, BIRC5-high was associated with young age (< 50 years) and Black race, as well as hormone receptor-negative tumors, non-Luminal A PAM50 subtypes, advanced stage, and larger tumors (> 2 cm). Relative to BIRC5-low, BIRC5-high tumors were associated with poor 5-year recurrence-free survival (RFS) among ER-positive tumors, both in unadjusted models [HR (95% CI): 2.7 (1.6, 4.6)] and after adjustment for age and stage [Adjusted HR (95% CI): 1.87 (1.07, 3.25)]. However, this relationship was not observed among ER-negative tumors [Crude HR (95% CI): 0.7 (0.39, 1.2); Adjusted HR (95% CI): 0.67 (0.37, 1.2)]. Conclusion Black and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes. Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent. Univariate, continuous BIRC5 expression was higher in breast tumors from Black women relative to non-Black women in both estrogen receptor (ER)-positive and ER-negative tumors and in analyses stratified by stage (i.e., within Stage I, Stage II, and Stage III/IV tumors). Within CBCS and TCGA, BIRC5-high was associated with young age (< 50 years) and Black race, as well as hormone receptor-negative tumors, non-Luminal A PAM50 subtypes, advanced stage, and larger tumors (> 2 cm). Relative to BIRC5-low, BIRC5-high tumors were associated with poor 5-year recurrence-free survival (RFS) among ER-positive tumors, both in unadjusted models [HR (95% CI): 2.7 (1.6, 4.6)] and after adjustment for age and stage [Adjusted HR (95% CI): 1.87 (1.07, 3.25)]. However, this relationship was not observed among ER-negative tumors [Crude HR (95% CI): 0.7 (0.39, 1.2); Adjusted HR (95% CI): 0.67 (0.37, 1.2)]. Black and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes. |
| ArticleNumber | 50 |
| Audience | Academic |
| Author | Nsonwu-Farley, Joseph Kirk, Erin L Walens, Andrea Abdou, Yara Carey, Lisa A Gao, Xiaohua Van Alsten, Sarah C Troester, Melissa A Olsson, Linnea T Perou, Charles M Hamilton, Alina M |
| Author_xml | – sequence: 1 givenname: Alina M surname: Hamilton fullname: Hamilton, Alina M organization: Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA – sequence: 2 givenname: Andrea surname: Walens fullname: Walens, Andrea organization: Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA – sequence: 3 givenname: Sarah C surname: Van Alsten fullname: Van Alsten, Sarah C organization: Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA – sequence: 4 givenname: Linnea T surname: Olsson fullname: Olsson, Linnea T organization: Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA – sequence: 5 givenname: Joseph surname: Nsonwu-Farley fullname: Nsonwu-Farley, Joseph organization: Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA – sequence: 6 givenname: Xiaohua surname: Gao fullname: Gao, Xiaohua organization: Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA – sequence: 7 givenname: Erin L surname: Kirk fullname: Kirk, Erin L organization: Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA – sequence: 8 givenname: Charles M surname: Perou fullname: Perou, Charles M organization: Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599, USA – sequence: 9 givenname: Lisa A surname: Carey fullname: Carey, Lisa A organization: Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599, USA – sequence: 10 givenname: Melissa A surname: Troester fullname: Troester, Melissa A organization: Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA – sequence: 11 givenname: Yara surname: Abdou fullname: Abdou, Yara email: Yara_Abdou@med.unc.edu, Yara_Abdou@med.unc.edu organization: Department of Medicine, Division of Oncology, University of North Carolina at Chapel Hill, 101 Manning Drive, CB# 7305, Chapel Hill, NC, 27514, USA. Yara_Abdou@med.unc.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38515208$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkltrVDEUhYNU7M0_4IMEfPHBU3NPzpPUwcvAQEEq-BaSnGTMcCYZkzPF-femnVo7RQJJSNb6NnuzTsFRyskD8AqjC4yVeF8xRVx1iLAOYdmTbvcMnGAmeMcZ-XH06H4MTmtdoaZSXL0Ax1RxzAlSJ2Dxcf5txqH_vSm-1pgTtDtYjPPvoFl6aNIA3RhTdGaEwbgplwpjExVv6gSdSc4XuDFT9Gmq5-B5MGP1L-_PM_D986fr2dducfVlPrtcdK6VnTrLe0q5tUL0xAbDe4uEotQzRgnthyC44W0nzIYBcSG8pFIEJBBFgQ2U0jMw33OHbFZ6U-LalJ3OJuq7h1yW2pQputFrIq1AzhPP-MCctX1QgRuGrHLWtAKN9WHP2mzt2g-u9VHMeAA9_Enxp17mG41RzwURrBHe3hNK_rX1ddLrWJ0fR5N83lZNesna6BFBTfrmiXSVtyW1WWmKqFRC9lT9Uy1N6yCmkFthdwvVl1JJLDnGvKku_qNqa_Dr6FpSQmzvBwayN7iSay0-PDSJkb4NlN4HSrdA6btA6V0zvX48ngfL3wTRPwSQxgI |
| Cites_doi | 10.1186/s12935-016-0326-1 10.1200/JCO.2019.37.15_suppl.2016 10.1093/jnci/djz206 10.2105/AJPH.2006.102525 10.1373/clinchem.2006.071613 10.1371/journal.pone.0004531 10.1007/BF00694745 10.1007/s10549-006-9240-x 10.1158/1055-9965.epi-21-1312 10.1200/JCO.2015.62.2126 10.1007/s10549-017-4166-z 10.1016/j.cell.2018.03.022 10.1007/s11523-013-0300-y 10.1038/nm0897-917 10.1016/j.adcanc.2022.100037 10.1001/jamasurg.2013.1680 10.1016/s0304-3835(03)00518-4 10.1093/jnci/djp175 10.1155/2019/3483192 10.1186/1471-2407-13-449 10.3892/or.2013.2502 10.1001/jama.295.21.2492 10.1158/1078-0432.CCR-08-0954 10.1158/1078-0432.CCR-10-1533 10.3322/caac.21555 10.2105/AJPH.2014.302386 10.1038/s41419-022-05539-5 10.1093/jnci/djx135 10.1186/s12920-015-0129-6 10.1007/s40259-013-0058-x 10.1093/annonc/mdj121 10.1248/bpb.30.2279 10.1056/NEJMoa041588 10.1007/s00262-016-1890-x 10.1038/sj.bjc.6603616 10.3892/ijo.21.2.315 10.1158/0008-5472.CAN-06-1927 10.1093/bib/bbaa163 10.1016/j.biopha.2006.06.008 10.1373/clinchem.2004.039149 10.3390/cancers13092209 10.1093/jnci/djaa215 10.1001/jama.2014.17322 10.1073/pnas.072586399 10.1186/s13058-020-01297-4 10.1056/NEJM199908053410614 10.1200/JCO.2008.18.1370 10.1093/jnci/djr543 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TO 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PIMPY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s13058-024-01792-y |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest - Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1465-542X |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_27b60ce2e45d4cbb9f8f5a40b8cba4bf A787175115 10_1186_s13058_024_01792_y 38515208 |
| Genre | Journal Article |
| GeographicLocations | North Carolina |
| GeographicLocations_xml | – name: North Carolina |
| GrantInformation_xml | – fundername: Susan G. Komen grantid: OGUNC1202 – fundername: NCI NIH HHS grantid: T32 CA057726 |
| GroupedDBID | --- 04C 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ACGFO ACGFS ACJQM ACMJI ACPRK ACRMQ ADBBV ADFRT ADINQ ADUKV AENEX AFKRA AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BMSDO BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DU5 E3Z EBD EBLON EBS ECM EIF EIHBH F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO ICW IHR INH INR ITC KQ8 LGEZI LOTEE NADUK NPM NXXTH O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RBZ ROL RPM RSV SBL SOJ TR2 U2A UKHRP WOQ AAYXX AFPKN CITATION ABVAZ AFGXO AFNRJ ZA5 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c515t-b59335bb6692bfa59b06833e443239df65a5df624bfd0566e7376f06030f4d333 |
| IEDL.DBID | RPM |
| ISSN | 1465-542X 1465-5411 |
| IngestDate | Tue Oct 22 15:16:33 EDT 2024 Tue Sep 17 21:29:12 EDT 2024 Wed Nov 06 16:49:53 EST 2024 Fri Nov 08 20:42:02 EST 2024 Wed Mar 27 18:02:25 EDT 2024 Tue Nov 12 23:45:36 EST 2024 Thu Sep 12 18:41:15 EDT 2024 Sat Nov 02 12:28:54 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c515t-b59335bb6692bfa59b06833e443239df65a5df624bfd0566e7376f06030f4d333 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10956264/ |
| PMID | 38515208 |
| PQID | 3037867938 |
| PQPubID | 2034567 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_27b60ce2e45d4cbb9f8f5a40b8cba4bf pubmedcentral_primary_oai_pubmedcentral_nih_gov_10956264 proquest_miscellaneous_2974001020 proquest_journals_3037867938 gale_infotracmisc_A787175115 gale_infotracacademiconefile_A787175115 crossref_primary_10_1186_s13058_024_01792_y pubmed_primary_38515208 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-03-21 |
| PublicationDateYYYYMMDD | 2024-03-21 |
| PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Breast cancer research : BCR |
| PublicationTitleAlternate | Breast Cancer Res |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | KS Albain (1792_CR36) 2009; 101 S Yao (1792_CR6) 2021 M Zhang (1792_CR43) 2014; 9 I Sušac (1792_CR20) 2019; 3483192–3483192 L O'Driscoll (1792_CR48) 2003; 201 PN Span (1792_CR49) 2006; 52 Y Abdou (1792_CR8) 2020; 22 B Wallden (1792_CR19) 2015; 8 U Mehraj (1792_CR24) 2022; 4 H Garg (1792_CR27) 2016; 16 L Kostadima (1792_CR23) 2006; 100 J Iqbal (1792_CR38) 2015; 313 N Oparina (1792_CR41) 2021; 13 CE De Santis (1792_CR1) 2019; 69 B Newman (1792_CR28) 1995; 35 A Bhattacharya (1792_CR33) 2021; 22 PN Span (1792_CR21) 2004; 50 J Lu (1792_CR15) 2009; 15 AM Hamilton (1792_CR32) 2022 CA Parise (1792_CR4) 2013; 13 C Garlapati (1792_CR42) 2023; 14 KM O'Brien (1792_CR25) 2010; 16 LA Carey (1792_CR26) 2006; 295 LA Cooper (1792_CR30) 2015; 105 M Sarti (1792_CR44) 2013; 30 T Keenan (1792_CR5) 2015; 33 BM Ryan (1792_CR10) 2006; 17 K Tanaka (1792_CR13) 2000; 6 JA Sparano (1792_CR37) 2012; 104 DN Martin (1792_CR7) 2009; 4 MA Troester (1792_CR31) 2018 AR Hinnis (1792_CR11) 2007; 96 B Groner (1792_CR45) 2014; 28 DM Sohn (1792_CR22) 2006; 60 F Liu (1792_CR14) 2007; 30 EC Smith (1792_CR2) 2013; 148 HS Swana (1792_CR17) 1999; 341 HC Benefield (1792_CR40) 2020; 112 L Sui (1792_CR12) 2002; 21 G Ambrosini (1792_CR9) 1997; 3 KA Hoadley (1792_CR35) 2018; 173 MS Ahluwalia (1792_CR47) 2019; 37 RB Warnecke (1792_CR29) 2008; 98 RA Fenstermaker (1792_CR46) 2016; 65 K Amend (1792_CR3) 2006; 66 JS Parker (1792_CR34) 2009; 27 J Tran (1792_CR16) 2002; 99 GH Rauscher (1792_CR39) 2017; 163 S Paik (1792_CR18) 2004; 351 |
| References_xml | – volume: 16 start-page: 49 year: 2016 ident: 1792_CR27 publication-title: Cancer Cell Int doi: 10.1186/s12935-016-0326-1 contributor: fullname: H Garg – volume: 37 start-page: 2016 year: 2019 ident: 1792_CR47 publication-title: JCO doi: 10.1200/JCO.2019.37.15_suppl.2016 contributor: fullname: MS Ahluwalia – volume: 112 start-page: 728 year: 2020 ident: 1792_CR40 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djz206 contributor: fullname: HC Benefield – volume: 98 start-page: 1608 year: 2008 ident: 1792_CR29 publication-title: Am J Public Health doi: 10.2105/AJPH.2006.102525 contributor: fullname: RB Warnecke – volume: 52 start-page: 1693 year: 2006 ident: 1792_CR49 publication-title: Clin Chem doi: 10.1373/clinchem.2006.071613 contributor: fullname: PN Span – volume: 4 year: 2009 ident: 1792_CR7 publication-title: PLoS ONE doi: 10.1371/journal.pone.0004531 contributor: fullname: DN Martin – volume: 35 start-page: 51 year: 1995 ident: 1792_CR28 publication-title: Breast Cancer Res Treat doi: 10.1007/BF00694745 contributor: fullname: B Newman – volume: 100 start-page: 161 year: 2006 ident: 1792_CR23 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-006-9240-x contributor: fullname: L Kostadima – year: 2022 ident: 1792_CR32 publication-title: Cancer Epidemiol Biomark Prevent doi: 10.1158/1055-9965.epi-21-1312 contributor: fullname: AM Hamilton – volume: 33 start-page: 3621 year: 2015 ident: 1792_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.62.2126 contributor: fullname: T Keenan – volume: 163 start-page: 321 year: 2017 ident: 1792_CR39 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-017-4166-z contributor: fullname: GH Rauscher – volume: 173 start-page: 291 year: 2018 ident: 1792_CR35 publication-title: Cell doi: 10.1016/j.cell.2018.03.022 contributor: fullname: KA Hoadley – volume: 9 start-page: 349 year: 2014 ident: 1792_CR43 publication-title: Target Oncol doi: 10.1007/s11523-013-0300-y contributor: fullname: M Zhang – volume: 3 start-page: 917 year: 1997 ident: 1792_CR9 publication-title: Nat Med doi: 10.1038/nm0897-917 contributor: fullname: G Ambrosini – volume: 4 year: 2022 ident: 1792_CR24 publication-title: Adv Cancer Biol Metastasis doi: 10.1016/j.adcanc.2022.100037 contributor: fullname: U Mehraj – volume: 148 start-page: 516 year: 2013 ident: 1792_CR2 publication-title: JAMA Surg doi: 10.1001/jamasurg.2013.1680 contributor: fullname: EC Smith – volume: 201 start-page: 225 year: 2003 ident: 1792_CR48 publication-title: Cancer Lett doi: 10.1016/s0304-3835(03)00518-4 contributor: fullname: L O'Driscoll – volume: 101 start-page: 984 year: 2009 ident: 1792_CR36 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp175 contributor: fullname: KS Albain – volume: 3483192–3483192 start-page: 2019 year: 2019 ident: 1792_CR20 publication-title: J. Oncol doi: 10.1155/2019/3483192 contributor: fullname: I Sušac – volume: 13 start-page: 449 year: 2013 ident: 1792_CR4 publication-title: BMC Cancer doi: 10.1186/1471-2407-13-449 contributor: fullname: CA Parise – volume: 30 start-page: 824 year: 2013 ident: 1792_CR44 publication-title: Oncol Rep doi: 10.3892/or.2013.2502 contributor: fullname: M Sarti – volume: 295 start-page: 2492 year: 2006 ident: 1792_CR26 publication-title: JAMA doi: 10.1001/jama.295.21.2492 contributor: fullname: LA Carey – volume: 15 start-page: 1326 year: 2009 ident: 1792_CR15 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0954 contributor: fullname: J Lu – volume: 16 start-page: 6100 year: 2010 ident: 1792_CR25 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-1533 contributor: fullname: KM O'Brien – volume: 69 start-page: 211 year: 2019 ident: 1792_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21555 contributor: fullname: CE De Santis – volume: 105 start-page: S374 issue: Suppl 3 year: 2015 ident: 1792_CR30 publication-title: Am J Public Health doi: 10.2105/AJPH.2014.302386 contributor: fullname: LA Cooper – volume: 14 start-page: 12 year: 2023 ident: 1792_CR42 publication-title: Cell Death Dis doi: 10.1038/s41419-022-05539-5 contributor: fullname: C Garlapati – year: 2018 ident: 1792_CR31 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djx135 contributor: fullname: MA Troester – volume: 8 start-page: 54 year: 2015 ident: 1792_CR19 publication-title: BMC Med Genom doi: 10.1186/s12920-015-0129-6 contributor: fullname: B Wallden – volume: 28 start-page: 27 year: 2014 ident: 1792_CR45 publication-title: BioDrugs doi: 10.1007/s40259-013-0058-x contributor: fullname: B Groner – volume: 17 start-page: 597 year: 2006 ident: 1792_CR10 publication-title: Ann Oncol doi: 10.1093/annonc/mdj121 contributor: fullname: BM Ryan – volume: 30 start-page: 2279 year: 2007 ident: 1792_CR14 publication-title: Biol Pharm Bull doi: 10.1248/bpb.30.2279 contributor: fullname: F Liu – volume: 351 start-page: 2817 year: 2004 ident: 1792_CR18 publication-title: N Engl J Med doi: 10.1056/NEJMoa041588 contributor: fullname: S Paik – volume: 65 start-page: 1339 year: 2016 ident: 1792_CR46 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-016-1890-x contributor: fullname: RA Fenstermaker – volume: 96 start-page: 639 year: 2007 ident: 1792_CR11 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603616 contributor: fullname: AR Hinnis – volume: 21 start-page: 315 year: 2002 ident: 1792_CR12 publication-title: Int J Oncol doi: 10.3892/ijo.21.2.315 contributor: fullname: L Sui – volume: 66 start-page: 8327 year: 2006 ident: 1792_CR3 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-1927 contributor: fullname: K Amend – volume: 22 start-page: bbaa163 year: 2021 ident: 1792_CR33 publication-title: Brief Bioinform doi: 10.1093/bib/bbaa163 contributor: fullname: A Bhattacharya – volume: 60 start-page: 289 year: 2006 ident: 1792_CR22 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2006.06.008 contributor: fullname: DM Sohn – volume: 50 start-page: 1986 year: 2004 ident: 1792_CR21 publication-title: Clin Chem doi: 10.1373/clinchem.2004.039149 contributor: fullname: PN Span – volume: 13 start-page: 2209 year: 2021 ident: 1792_CR41 publication-title: Cancers doi: 10.3390/cancers13092209 contributor: fullname: N Oparina – year: 2021 ident: 1792_CR6 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djaa215 contributor: fullname: S Yao – volume: 313 start-page: 165 year: 2015 ident: 1792_CR38 publication-title: JAMA doi: 10.1001/jama.2014.17322 contributor: fullname: J Iqbal – volume: 99 start-page: 4349 year: 2002 ident: 1792_CR16 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.072586399 contributor: fullname: J Tran – volume: 22 start-page: 62 year: 2020 ident: 1792_CR8 publication-title: Breast Cancer Res doi: 10.1186/s13058-020-01297-4 contributor: fullname: Y Abdou – volume: 341 start-page: 452 year: 1999 ident: 1792_CR17 publication-title: N Engl J Med doi: 10.1056/NEJM199908053410614 contributor: fullname: HS Swana – volume: 27 start-page: 1160 year: 2009 ident: 1792_CR34 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.1370 contributor: fullname: JS Parker – volume: 104 start-page: 406 year: 2012 ident: 1792_CR37 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djr543 contributor: fullname: JA Sparano – volume: 6 start-page: 127 year: 2000 ident: 1792_CR13 publication-title: Clin Cancer Res contributor: fullname: K Tanaka |
| SSID | ssj0017858 |
| Score | 2.4671702 |
| Snippet | Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not... Abstract Purpose Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target.... Purpose Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5... PurposeSurvivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5... Abstract Purpose Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target.... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 50 |
| SubjectTerms | Age Apoptosis Binomial distribution Black or African American Black people Breast cancer Breast Neoplasms - pathology Cancer Cancer patients Cancer therapies Care and treatment Cell cycle Estrogen Estrogen receptors Estrogens Female Gene expression Generalized linear models Genetic aspects Genomes Genomics Health aspects Humans Medical colleges Medical prognosis Medical records Middle Aged Mortality Oncology, Experimental Patients Population studies Prognosis Self report Survivin Survivin - genetics Therapeutic targets Tumors Variables White people Womens health |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hHlAvCNoCgYKMVMEBrGb9inPcVlSlohwQlXqz4pfooSna3Urdf9-x46w24sCFSw5rO0rmm-dm_BngiDWR8dgq2gjhqYhMUh29pyF2MxF8K7VP-50vf6jzK3FxLa-3jvpKPWEDPfAguGPWWFW7wIKQXjhr26ij7ERttbOdsDF737odi6ny_aDRUo9bZLQ6XqKnlppiPKJJAxldT8JQZuv_2ydvBaVpw-RWBDp7Ds9K6kjmwyO_gCeh34P9eY9l8-2afCS5mTP_S74HTy_LN_N9-H7y7eepJOGhtLz2xK7JonPhC0FfQrrek3F7JCmn75AbnJS61VfEJa1YkEK_ujyAq7Ovv07PaTlDgTrMVFbUypZzaa1SLbOxk62tleY8CMEZb31UspN4ZShJj7mQCg16nFgrtP0oPOf8Jez0d314DaSxrrZRhM4qJ6Kf4WodsMbFe1guo6jg8yhS82egyjC5xNDKDAAYBMBkAMy6gpMk9c3MRHOdf0DwTQHf_Av8Cj4lzEwyRgTGdWVPAT5worUyc3RHmB9h1lvB4WQmGpGbDo-om2LES4PRvUl8hFxX8GEznFamxrQ-3N0vDcN6LPPy1RW8GpRk80ocs1nJalytJ-ozeefpSH_zO1N8zxI_JOaqb_6HlN7CLsuqzymbHcLOanEf3mEqtbLvs9U8AqVoHLY priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgLKi2PtAUZCcEBrCZ-xTlV24qqIMoBUWlvVvwqPZBtN1uJ_feMHWfbCIlLDrEd2Z6HZ5yZbxB6R-tAWWgkqTl3hAcqiArOER_ainvXCOVivvP5d3l2wb_OxTxfuPU5rHLUiUlRu4WNd-SHoGrrCA7H1NH1DYlVo-Lf1VxC4yF6VNFSxpCuer5xuGLheTVkFwkieFWNSTNKHvagu4UicEKRyJOUrCcHU8Lv_1dL3zumpiGU986k0230NBuTeDZQ_xl64LsdtDvrwJH-vcbvcQrvTPfmO-jxef6Lvou-HX_5cSKw_5ODYDts1njZWv8Jg3bBbefwmDCJcz0efAWdYvz6CtvIJ0ucAVn75-ji9PPPkzOSqyoQC7bLihjRMCaMkbKhJrSiMbBxjHnOGWWNC1K0Ap6Um-DAOpK-Bh0USgnaIHDHGHuBtrpF518hXBtbmsB9a6TlwVUwWnnweuEbhonAC_Rx3FJ9PYBn6OR0KKkHAmgggE4E0OsCHcdd3_SMwNfpxWJ5qbMcaVobWVpPPReOW2OaoIJoeWmUNS1MuUAfIs10FE8gjG1zlgFMOAJd6RkoKLCYwA4u0MGkJ4iVnTaPVNdZrHt9x4QFertpjiNjqFrnF7e9puChJaS-skAvBybZLImBfStoCaPVhH0ma562dFe_Euh3FREjwXrd-_-89tETmpiaEVodoK3V8ta_BrNpZd4k2fgLIs0UNw priority: 102 providerName: ProQuest |
| Title | BIRC5 expression by race, age and clinical factors in breast cancer patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38515208 https://www.proquest.com/docview/3037867938 https://www.proquest.com/docview/2974001020 https://pubmed.ncbi.nlm.nih.gov/PMC10956264 https://doaj.org/article/27b60ce2e45d4cbb9f8f5a40b8cba4bf |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Lb9MwGLe2ISEuCDYegVEZCcEBvKZ-xTm21aaB6DRVTKq4WPFrVKLp1HYS_e_57CbVIm5cfIjtyPH3dr7vZ4Q-0CJQFkpJCs4d4YEKooJzxIdqwL0rhXKx3nlyJS9v-LeZmB0g2dbCpKR9a-Zn9e_FWT3_lXIr7xa23-aJ9a8n40FEzwNL3j9Eh8ChbYze_DsoVLqVE1SAIIIPBm2pjJL9NWhsoQjYJRI5kZJtxxwl1P5_dfMD49RNnHxgiS6eoaeNC4mHu6U-Rwe-PkYnwxrC58UWf8QpqTOdlh-jx5Pm3_kJ-j76Oh0L7P80qa81Nlu8qqz_gkGn4Kp2uC2TxM0tPHgOg2LW-gbbyB0r3MCwrl-gm4vzH-NL0tylQCx4LBtiRMmYMEbKkppQidLkUjHmOWeUlS5IUQloKTfBgU8kfQGaJ-QSdEDgjjH2Eh3Vy9q_RrgwNjeB-8pIy4MbwGzlIdaFdxgmAs_Q53ZL9d0OMkOnUENJvSOABgLoRAC9zdAo7vp-ZIS7Tg-Wq1vdEF3Twsjceuq5cNwaUwYVRMVzo6ypYMkZ-hRppqNQAmFs1dQWwIIjvJUegloCPwm83wyddkaCMNlud0t13QjzWoOVLyIuIVMZer_vjjNjglrtl_drTSEuS_h8eYZe7Zhk_0kMvFpBc5itOuzT-eZuD3B-gvpuOf3N_099i57QxPCM0MEpOtqs7v07cKQ2pgfSMyt66NHo_Op62kvHEdBORz97SaL-AmbEIEs |
| link.rule.ids | 230,315,730,783,787,867,888,2109,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELaglYALgpbHQgEjITiA1V2_1ntCSdUqhSRCVSv1Zq1f0AObkqQS-feMHSd0hcQlh7UdeXdmPs_Y428QekfrQFloJKk5d4QHKogKzhEf2op71wjl4n3nyVSOLviXS3GZN9wWOa1yg4kJqN3Mxj3yQ4DaOpLDMfX5-heJVaPi6WouoXEX7UaqKgi-dofH029n23OEWqUKnQAHggheVZtrM0oeLgC9hSKwRpGolZSsektTYvD_F6dvLVT9JMpbq9LJI_Qwu5N4sJb_Y3THd3tof9BBKP1zhd_jlOCZds730L1JPkffR-Ph6dmRwP53ToPtsFnheWv9Jwz4gtvO4c2VSZwr8uAr6BQz2JfYRk2Z40zJuniCLk6Oz49GJNdVIBa8lyUxomFMGCNlQ01oRWNKqRjznDPKGhekaAX8Um6CA_9I-hpQKJQS8CBwxxh7ina6WeefI1wbW5rAfWuk5cFVMFp5iHvhPwwTgRfo4-aT6us1fYZOYYeSei0ADQLQSQB6VaBh_OrbnpH6Oj2Yzb_rbEma1kaW1lPPhePWmCaoIFpeGmVNC1Mu0IcoMx0NFARj23zPACYcqa70ACAKfCbwhAt00OsJhmX7zRup62zYC_1XDQv0dtscR8Zktc7PbhaaQoyWuPrKAj1bK8n2lRh4uIKWMFr11Kf3zv2W7upHov2uImck-K8v_j-vN-j-6Hwy1uPT6deX6AFNCs4IrQ7QznJ-41-BE7U0r7Ol_AH8WBiN |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9MwGLZgSBMXBBuwwAAjITiA18RfcY5dodpgnSbEpN2s2LGhEk2rtpPov-e161SLuHHJIbYjO-938vgxQu9o6SnzlSQl5w3hngqifNMQ5-uCu6YSqgn7nSeX8uyaf70RNwlVuUqwytaa6Un7e3bSTn9FbOViZgcdTmxwNRkVgT0PIvlg0fjBffQAjDaXXaWe_iCUKp7NCY5AEMGLotswo-RgBX5bKALRiQR9pGTTC0qRu_9fD30nRPXhk3fi0fgxepQSSTzcTvgJuufaA3Q4bKGInm3wexyhnfGb-QHan6Q_6Ifo4vT8-0hg9ycBYFtsNnhZW_cJg2fBddvgbrMkTmfx4Cl0Ctj1NbZBR5Y4kbGunqLr8ZcfozOSTlQgFvKWNTGiYkwYI2VFja9FZXKpGHOcM8qqxktRC7hSbnwDmZF0Jfgfn0vwBJ43jLFnaK-dt-4I4dLY3HjuaiMt900Bo5WDiheeYZjwPEMfu1eqF1viDB0LDiX1VgAaBKCjAPQmQ6fhre96BtLreGO-_KmT6DUtjcyto46LhltjKq-8qHlulDU1TDlDH4LMdDBNEIyt0w4DmHAgudJDcE6QLUEOnKHjXk8wKdtv7qSuk0mvNMT6MrATMpWht7vmMDLA1Fo3v11pCtVZZOnLM_R8qyS7JTHIbQXNYbTqqU9vzf0W0P9I-N3p-4v_H_oG7V99HuuL88tvL9FDGnWfEVoco7318ta9gsxqbV5HE_oLjZ4gLw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=BIRC5+expression+by+race%2C+age+and+clinical+factors+in+breast+cancer+patients&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Hamilton%2C+Alina+M.&rft.au=Walens%2C+Andrea&rft.au=Van+Alsten%2C+Sarah+C.&rft.au=Olsson%2C+Linnea+T.&rft.date=2024-03-21&rft.issn=1465-542X&rft.eissn=1465-542X&rft.volume=26&rft.issue=1&rft_id=info:doi/10.1186%2Fs13058-024-01792-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13058_024_01792_y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon |